Overview

Local Antibiotic Delivery for Community Acquired Pneumonia

Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blinded clinical pilot study to assess whether addition of inhaled levofloxacin 240 mg twice daily for three days leads to improved or worsened physiological status in CAP patients with and without pre-existing lung disease.
Phase:
PHASE2
Details
Lead Sponsor:
Copenhagen Respiratory Research
Treatments:
Levofloxacin